Publications dans lesquelles il/elle collabore avec Ángel Fernando Panizo Santos (7)

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2017

  1. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

2009

  1. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

    British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883

2004

  1. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

    Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761

2003

  1. Adult stem cells for myocardial repair

    BASIC AND APPLIED MYOLOGY, Vol. 13, Núm. 1, pp. 15 - 22

2000

  1. Clinico-pathologic, immunohistochemical, and TUNEL study in early cardiac allograft failure

    Cardiovascular Pathology, Vol. 9, Núm. 3, pp. 153-159